BNTX logo

BioNTech SE (BNTX)

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell...

NASDAQHealthcareBiotechnologyUSA

Company Profile

Stock Code
BNTX
ISIN Code
US09075V1026
Currency
US Dollar (USD)
IPO Date
2019-10-10

Contact Information

Company Address
An der Goldgrube 12, Mainz, Germany, 55131
Contact Phone
49 6131 9084
Company Website
https://www.biontech.de
Fiscal Year End
December

Financial Highlights

Market Capitalization
$999,999.99
Gross Profit (TTM)
$999,999.99
Return on Assets (TTM)
-4.18%
EBITDA
$-999,999.99
Revenue (TTM)
$999,999.99